For US HealthcareColo. Rev. Stat. § 12-280-308 requires pharmaceutical manufacturers, when engaging in prescription drug marketing, to provide the wholesale acquisition cost (WAC) of the drug to Colorado prescribers. Under Colorado law, the names of generic prescription drugs (if available) from the same therapeutic class (i.e., same or similar mechanism of action used to treat a specific condition) shall also be provided.
Connecticut Public Act No. 23-171 requires the disclosure of the list price of a legend drug when a pharmaceutical representative provides information concerning such legend drug to prescribing practitioners or pharmacists, based on the dose and quantity of such legend drug as described in the medication package insert.
Vermont law 33 V.S.A. §2005a mandates that pharmaceutical manufacturers disclose to Vermont physicians and other prescribers the average wholesale price (AWP) of drugs they market within the state as well as the prices of other drugs in the same therapeutic class. Under Vermont law, "therapeutic class" is defined as the therapeutic class listed in the 2004 American Hospital Formulary Service Pharmacologic-Therapeutic Classification published by the American Society of Health System Pharmacists (available at https://www.ashp.org).
RAPIBLYK® is contraindicated in patients with:
Patients with hemodynamic compromise, hypovolemia, or receiving interacting medications are at increased risk of hypotension. Monitor blood pressure closely. Reduce or discontinue RAPIBLYK if hypotension occurs.
Bradycardia, including sinus pause, heart block, severe bradycardia, and cardiac arrest, may occur. Monitor heart rate and rhythm. Reduce or discontinue RAPIBLYK for bradyarrhythmia.
Beta-blockers may cause depression of myocardial contractility and may precipitate heart failure or cardiogenic shock. At the first sign of impending cardiac failure, discontinue RAPIBLYK and initiate supportive therapy.
Beta-blockers may exacerbate bronchospasm. Use caution in patients with reactive airway disease. Discontinue infusion if bronchospasm occurs.
Beta-blockers may mask symptoms of hypoglycemia (e.g., tachycardia) and may increase the risk for severe or prolonged hypoglycemia. Monitor blood glucose in patients with diabetes or those at risk.
Infusion site reactions including pain, swelling, and erythema have occurred. Avoid infusions into small veins or through butterfly catheters. Use an alternative site if reactions develop.
Abrupt discontinuation of beta-blocker therapy in patients with coronary artery disease may result in exacerbations of angina, myocardial infarction, or ventricular arrhythmias. Monitor for signs of myocardial ischemia when discontinuing RAPIBLYK.
Beta-blockers may increase serum potassium. Monitor electrolytes during therapy, especially in patients with renal impairment.
Beta-adrenergic blockade may mask clinical signs of hyperthyroidism. Abrupt withdrawal may precipitate thyroid storm.
Patients at risk of anaphylaxis may be more reactive to allergen exposure and may be unresponsive to usual doses of epinephrine.
The most common adverse reaction was hypotension in adults and pediatric patients.
For more information about RAPIBLYK, see full Prescribing Information.
RAPIBLYK® (landiolol) for injection is a beta-adrenergic blocker indicated for the short-term reduction of ventricular rate in: